Albert David . Receives 'Buy' Rating from MarketsMOJO for Strong Financial Performance and Positive Outlook

Albert David ., a microcap pharmaceutical company, has recently received a 'Buy' rating from MarketsMOJO. This upgrade is based on the company's strong financial performance and positive outlook.
One of the key factors contributing to the 'Buy' rating is the company's low Debt to Equity ratio, which is currently at 0 times. This indicates a healthy financial position and the ability to manage debt effectively.

In addition, Albert David . has consistently delivered positive results for the last 4 quarters, with a significant growth in profits. The company's Profit After Tax (HY) has grown by 121.50%, while its Return on Capital Employed (HY) is at an impressive 25.27%. The company also has a high amount of cash and cash equivalents, with Rs 31.16 crore in its reserves.

From a technical standpoint, the stock is currently in a bullish range and has shown improvement in its trend. Multiple factors, such as MACD, Bollinger Band, and KST, indicate a bullish outlook for the stock.

Moreover, with a Return on Equity (ROE) of 19.7, the company has a very attractive valuation with a Price to Book Value of 1.9. This suggests that the stock is trading at a fair value compared to its historical valuations. In the past year, the stock has generated a return of 107.19%, while its profits have increased by 108.5%. The company's PEG ratio of 0.1 further supports its attractive valuation.

Albert David . has also shown consistent returns over the last 3 years, outperforming the BSE 500 index in each of the last 3 annual periods.

However, there are some risks associated with investing in the company. One of them is the slow long-term growth, as the company's Net Sales have only grown by an annual rate of 2.72% over the last 5 years. Additionally, despite being a microcap company, domestic mutual funds hold a very small stake in the company, which may indicate a lack of confidence in the company's stock or business.

In conclusion, Albert David . is a promising pharmaceutical company with a strong financial position and positive outlook. Its recent 'Buy' rating from MarketsMOJO is a testament to its potential for growth and attractive valuation. However, investors should also consider the risks associated with the company before making any investment decisions.